51 related articles for article (PubMed ID: 9592638)
1. Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management. INNOV Study Group.
Penfornis A; Millot L
Diabetes Metab; 1998 Apr; 24(2):137-42. PubMed ID: 9592638
[TBL] [Abstract][Full Text] [Related]
2. Inpatient or outpatient initiation of insulin therapy. Experience and cost effective analysis in a suboptimal clinical setting.
Mengistu M; Lungi Y; Mamo F
Trop Geogr Med; 1991; 43(1-2):180-3. PubMed ID: 1750112
[TBL] [Abstract][Full Text] [Related]
3. [Initiating insulin therapy in patients with diabetes mellitus type 2: in a transmural setting is at least as effective as in an outpatient setting; a retrospective study with a 4-year follow-up].
Rosendal H; Vondeling H; de Witte LP; Hutubessy RC; van Beekum WT; Heine RJ
Ned Tijdschr Geneeskd; 2002 Jan; 146(4):166-71. PubMed ID: 11845567
[TBL] [Abstract][Full Text] [Related]
4. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
Meneghini L; Koenen C; Weng W; Selam JL
Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
[TBL] [Abstract][Full Text] [Related]
5. Should insulin therapy in type 2 diabetic patients be started on an out- or inpatient basis? Results of a prospective controlled trial using the same treatment and teaching programme in ambulatory care and a university hospital.
Müller UA; Müller R; Starrach A; Hunger-Dathe W; Schiel R; Jörgens V; Grüsser M
Diabetes Metab; 1998 Jun; 24(3):251-5. PubMed ID: 9690059
[TBL] [Abstract][Full Text] [Related]
6. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
7. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
8. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
9. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
10. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
Gao Y; Guo XH; Vaz JA;
Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
[TBL] [Abstract][Full Text] [Related]
11. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
12. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
Khutsoane D; Sharma SK; Almustafa M; Jang HC; Azar ST; Danciulescu R; Shestakova M; Ayad NM; Guler S; Bech OM;
Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
Ross SA; Zinman B; Campos RV; Strack T;
Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
[TBL] [Abstract][Full Text] [Related]
17. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
[TBL] [Abstract][Full Text] [Related]
18. [Outpatient insulin therapy in type II diabetes: program evaluation and calculation of cost saving].
Micaló Durán T; Romera Parra M; Recasens Gracia A; Pé Estella P; Brosa Linares F
Med Clin (Barc); 1991 Jun; 97(3):81-5. PubMed ID: 1890897
[TBL] [Abstract][Full Text] [Related]
19. Are we helping or harming our insulin-treated diabetic patients during ambulatory treatment?
Szcześniak G; Dziemidok P; Paprzycki PS
Ann Agric Environ Med; 2013; 20(2):346-50. PubMed ID: 23772589
[TBL] [Abstract][Full Text] [Related]
20. [Cost effectiveness and evaluation of a structured therapy and education program for insulin-treated type II diabetic patients in Bradenburg].
Schlottmann N; Grüsser M; Hartmann P; Jörgens V
Z Arztl Fortbild (Jena); 1996 Aug; 90(5):441-4. PubMed ID: 9157737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
